Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016

Clinical Infectious Diseases(2020)10.1093/cid/ciaa286Source: DataRank Database

Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016 is a research paper published in Clinical Infectious Diseases (2020). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.15)OA: hybridTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Jonathan M. Wortham ORCID,Christine Ho ORCID,Krista M. Powell ORCID,Kristine M Schmit ORCID

Live enrichment

PubMed:32185390 PMC:PMC8020883 OpenAlex:https://openalex.org/W3010790804

Intramural CDC HHS

Grant: CC999999

FWCI

0.15

Citation Percentile

0.6%

Citation Trend

2021

2022

2023

hybridLicense: public-domain

journalhttps://academic.oup.com/cid/article-pdf/71/9/2502/34676612/ciaa286.pdf

publisherhttps://academic.oup.com/cid/article-pdf/71/9/2502/34676612/ciaa286.pdf

publisherhttp://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa286/33166793/ciaa286.pdf

journalhttps://doi.org/10.1093/cid/ciaa286

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32185390

Fields of Study

Tuberculosis Research and EpidemiologyMycobacterium research and diagnosisPneumocystis jirovecii pneumonia detection and treatmentAntitubercular AgentsDrug Administration ScheduleDrug Therapy, CombinationHumansIsoniazidLatent TuberculosisMycobacterium tuberculosisRifampinUnited States

MeSH Terms

Antitubercular AgentsDrug Administration ScheduleDrug Therapy, CombinationHumansIsoniazidMycobacterium tuberculosisRifampinUnited StatesLatent Tuberculosis

Keywords

RifapentineMedicineIsoniazidLatent tuberculosisMycobacterium tuberculosisTuberculosisAdverse effectExtensively drug-resistant tuberculosisVirologyInternal medicinePathologyLatentAdverse

Sustainable Development Goals

SDG 0: Good health and well-being

Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016

FAIR Checklist

Authors (4)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)